Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. President and CEO K. Charles Janac reported indirect open-market sales of a total of 70,000 shares of common stock on June 8, 2026. The shares were sold by Bayview Legacy, LLC in two transactions at weighted average prices of $35.1596 and $34.7417, in multiple trades within disclosed price ranges. A footnote states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025. Following the transactions, Bayview Legacy, LLC held 8,929,071 shares indirectly, while Janac also held 196,729 shares directly and 56,252 shares through the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of 70,000 shares of AIP common stock. The sales occurred on June 8, 2026 in two tranches at weighted average prices of $34.7417 and $35.1596 per share.
The filing states that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. All holdings are reported as indirect, through Bayview Legacy, LLC, which is controlled by K. Charles Janac as manager.
The filing reports proposed and completed dispositions of Common stock by affiliated holders using 10b5-1 plans and private acquisitions. The excerpt lists multiple 10b5-1 sales by BAYVIEW LEGACY, LLC and one by K. CHARLES JANAC between 03/09/2026 and 05/08/2026, with individual sale quantities and dollar amounts recorded.
The filing also lists earlier private acquisitions from the issuer on 11/05/2013 (50,000 shares) and 02/05/2016 (20,000 shares). Transaction timing and per-sale proceeds are shown next to each sale date.
Arteris, Inc. director Antonio J. Viana reported indirect sales and gifts of Common Stock. On June 4, 2026, the Viana Family Trust, for which he is trustee, executed open-market sales totaling 20,839 shares of Arteris Common Stock in three blocks: 8,939 shares at a weighted average price of $37.089, 7,000 shares at $36.5082, and 4,900 shares at $35.4661, under a Rule 10b5-1 trading plan adopted on June 10, 2025. The filing also reports bona fide gifts totaling 41,678 shares, split between indirect trust holdings and his direct holdings, at a reported price of $0. Following these transactions, Viana reports 64,620 shares held indirectly through the Viana Family Trust and 4,704 shares held directly.
Arteris, Inc. director Joachim Kunkel received an equity grant of 4,703 shares of common stock in the form of restricted stock units (RSUs) as board compensation. The award carried no cash exercise price and increased his directly held position to 74,330 shares.
The 4,703 RSUs each represent a contingent right to one share of common stock and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, as long as he continues serving on the board. The grant was based on the average trading price of Arteris stock of $31.89 over the April 21, 2026 to June 2, 2026 period, and Kunkel elected to defer receipt of the shares.
Viana Antonio J reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Antonio J. Viana reported an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholder meeting, conditioned on his continued board service.
The grant was made on June 2, 2026, based on an average trading price of $31.89 for Arteris stock from April 21, 2026 through June 2, 2026. Following the grant, Viana holds 25,543 shares directly, including these RSUs, and 64,620 shares indirectly through the Viana Family Trust.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, if she continues serving on the board. The grant value was based on the average trading price of $31.89 over the period from April 21, 2026 through June 2, 2026. Following this award, she holds a total of 106,414 common shares directly, and has elected to defer receipt of the shares underlying this RSU grant.
Chitkara Raman reported acquisition or exercise transactions in this Form 4 filing.
Arteris director Raman Chitkara reported an equity award of 4,703 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, contingent on continued Board service. Following this award, Chitkara directly holds 147,570 shares, and has elected to defer receipt of the underlying shares once the RSUs vest.
Cantwell Wayne C reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Wayne C. Cantwell reported a compensation-related equity grant in common stock. He received 7,839 restricted stock units (RSUs), each representing one share of Arteris common stock. The RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, subject to his continued board service.
After this grant, Cantwell holds 42,571 shares directly. He also has indirect holdings of 189,698 shares through The Cantwell Living Trust, where he serves as trustee, and 38,761 shares through the Decathlon Capital Management 401K Plan FBO Wayne Cantwell. The grant was based on an average Arteris trading price of $31.89 over the period from April 21, 2026 through June 2, 2026, and the RSUs have no expiration date.
Arteris, Inc. director Saiyed Atiq Raza, through a revocable trust for which he serves as trustee, reported multiple stock transactions in the company’s common shares. On June 3, 2026, the trust sold a total of 20,839 shares in open‑market trades at weighted average prices of $37.1294, $38.4583 and $37.6541 per share, under a pre‑arranged Rule 10b5‑1 trading plan.
The filing also shows bona fide gifts totaling 41,678 shares and a separate grant of 4,703 restricted stock units on June 2, 2026, which vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting. Following these moves, the trust holds 160,839 shares and Raza’s direct holdings consist of 4,703 RSUs.